Atlas Trials

Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant

Clinical trial NCT04035876 · UNKNOWN

Trial details

NCT number
NCT04035876
Sponsor
Zhejiang University
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Hepatocellular CarcinomaLiver Transplant
Start date
2019-07-16
Primary completion
2021-12-31
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.